Journal of Medical Microbiology Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae non-PCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil --Manuscript Draft-Manuscript Number:
JMM-D-16-00266R1
Full Title:
Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae nonPCV10 serotype isolates recovered from meningitis cases in Salvador, Brazil
Short Title:
S. pneumoniae non-PCV10 serotypes from meningitis cases
Article Type:
Standard
Section/Category:
Microbial Epidemiology
Corresponding Author:
Leila Carvalho Campos, Ph.D. Centro de Pesquisas Goncalo Moniz Salvador, Bahia BRAZIL
First Author:
Jailton Azevedo, Ph.D.
Order of Authors:
Jailton Azevedo, Ph.D.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
Eder Silva dos Anjos, M.Sc. Soraia Machado Cordeiro, Ph.D. Milena Soares dos Santos, Ph.D. Eliane Cunegundes Escobar, B.Sc. Paulo Rocha Lobo, M.D. Maria da Gloria Carvalho, Ph.D. Mitermayer Galvão Reis, Ph.D., M.D. Joice Neves Reis, Ph.D. Leila Carvalho Campos, Ph.D. Abstract:
In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced to the Brazilian childhood vaccination program. Concerns have been raised that nonvaccine serotypes could increase in prevalence and reduce the benefits of vaccination; therefore, we examined the non-PCV10 isolates recovered from meningitis during pre (January, 2008-May, 2010) and post-vaccine (June, 2010-December, 2012) periods. Surveillance for pneumococcal meningitis was established at the Reference Hospital of Infectious Diseases in Salvador, Brazil. Serotypes were determined by multiplex PCR and/or Quellung reaction. Antimicrobial susceptibility testing was conducted by E-test and broth microdilution. Genotyping employed pulsed field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). A total of 148 cases of meningitis were identified from January 2008 to December 2012, 77 (52%) of which were due to nonPCV10 isolates, with 50 (52.1%) from pre-vaccine and 27 (52%) post-vaccine periods. In the post-vaccine period, the non-PCV10 serotypes 12F (n = 6; 22.2%), 10A (n = 3; 11.1%), 15B (n = 2; 7.4%), and 18B (n = 2; 7.4%) were the most prevalent. Forty-three isolates (55.8%) were non-susceptible to one or more antibiotics. Non-susceptibility to penicillin was observed among serotypes 19A (3 isolates), 9N (1 isolate), and 12F (1 isolate). PFGE and MLST results demonstrated a wide genetic diversity among the isolates. During the early period following PCV10 introduction, no obvious emergence of a particular serotype was evident among non-PCV10 strains. This study underscores the importance of monitoring any changes among non-PCV10 cases after the introduction of PCV10.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Manuscript Including References (Word document)
Click here to download Manuscript Including References (Word document) Campos_ms revised.docx 1
1
Genetic profiles and antimicrobial resistance of Streptococcus pneumoniae non-PCV10
2
serotypes isolates recovered from meningitis cases in Salvador, Brazil
3
Running Title: S. pneumoniae non-PCV10 serotypes from meningitis cases
4 5
Jailton Azevedo1, Éder Silva dos Anjos1, Soraia M. Cordeiro2, Milena S. dos Santos3,
6
Eliane C. Escobar1, Paulo R. Lobo1, Maria da Glória Carvalho4, Mitermayer G. Reis1,
7
Joice N. Reis1, 2, Leila C. Campos1*
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
8 9
1
Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, 40296-710, Brazil
10
2
Faculdade de Farmácia, Universidade Federal da Bahia, Salvador, Bahia, 40170-115,
11
Brazil
12
3
13
Bahia, Vitória da Conquista, Bahia, 45029-094, Brazil
14
4
15
30333, USA
16
Keywords: Streptococcus pneumoniae, genotype, PCV10, surveillance.
17
Subject Category: Microbial Epidemiology
18
Word Count: 3089
19
*Corresponding author: Laboratório de Patologia e Biologia Molecular, Instituto
20
Gonçalo Moniz, Fundação Oswaldo Cruz, 40296-710 Salvador, BA, Brazil. Tel.: +55
21
71 31762350. E-mail address:
[email protected] (L. C. Campos)
22 23 24 25
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Instituto Multidisciplinar em Saúde, Campus Anísio Teixeira, Universidade Federal da
Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta,
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
2
26
ABSTRACT
27
In 2010, the 10-valent pneumococcal conjugate vaccine (PCV10) was introduced to the
28
Brazilian childhood vaccination program. Concerns have been raised that non-vaccine
29
serotypes could increase in prevalence and reduce the benefits of vaccination; therefore,
30
we examined the non-PCV10 isolates recovered from meningitis during pre (January,
31
2008–May, 2010) and post-vaccine (June, 2010–December, 2012) periods. Surveillance
32
for pneumococcal meningitis was established at the Reference Hospital of Infectious
33
Diseases in Salvador, Brazil. Serotypes were determined by multiplex PCR and/or
34
Quellung reaction. Antimicrobial susceptibility testing was conducted by E-test and
35
broth microdilution. Genotyping employed pulsed field gel electrophoresis (PFGE) and
36
multilocus sequence typing (MLST). A total of 148 cases of meningitis were identified
37
from January 2008 to December 2012, 77 (52%) of which were due to non-PCV10
38
isolates, with 50 (52.1%) from pre-vaccine and 27 (52%) post-vaccine periods. In the
39
post-vaccine period, the non-PCV10 serotypes 12F (n = 6; 22.2%), 10A (n = 3; 11.1%),
40
15B (n = 2; 7.4%), and 18B (n = 2; 7.4%) were the most prevalent. Forty-three isolates
41
(55.8%) were non-susceptible to one or more antibiotics. Non-susceptibility to
42
penicillin was observed among serotypes 19A (3 isolates), 9N (1 isolate), and 12F (1
43
isolate). PFGE and MLST results demonstrated a wide genetic diversity among the
44
isolates. During the early period following PCV10 introduction, no obvious emergence
45
of a particular serotype was evident among non-PCV10 strains. This study underscores
46
the importance of monitoring any changes among non-PCV10 cases after the
47
introduction of PCV10.
48 49
INTRODUCTION
50
Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide,
51
causing diseases that range in severity from meningitis, septicaemia, and pneumonia, to
52
sinusitis and acute otitis media (WHO, 2012). Almost all isolates that cause these
53
infections are encapsulated, and to date, greater than 94 different pneumococcal
54
serotypes have been distinguished, expressing structurally and antigenically different
55
capsular polysaccharides (Geno et al., 2015). The capsule is the target of all licensed
56
vaccines (Feldman & Anderson, 2014).
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
3
57
The licensure and subsequent widespread use of pneumococcal conjugate vaccines has
58
decreased the overall incidence of invasive pneumococcal disease in many countries, in
59
part by also reducing carriage of vaccine-type strains, and inducing herd immunity
60
(Millar et al., 2008; Hammitt et al. 2014). However, concerns have been raised that non-
61
vaccine serotypes could increase in prevalence and reduce the benefits of vaccination
62
(Pilishvili et al., 2010).
63
The overall effect of the use of conjugate vaccines can include serotype replacement
64
and/or the capsular switching phenomenon. The contribution of each of these effects in
65
geographical areas where a conjugate vaccine is introduced is difficult to predict;
66
therefore, careful monitoring of the epidemiology and understanding of the dynamics of
67
the pneumococcal population is required to assess the initial and long-term benefits of
68
vaccination in each region. In 2010, Brazil introduced the 10-valent non-typable
69
Haemophilus influenzae protein D conjugate vaccine (PCV10 or PHiD-CV; GSK
70
Biologicals, Rixensart, Belgium) into its routine National Immunization Program, in a
71
three-dose scheme (2, 4, and 6 months) plus a booster at 12 months. This vaccine
72
contains antigens designed to protect against the serotypes 4, 9V, 14, 19F, 23F, 18C,
73
and 6B, in addition to serotypes 1, 5, and 7F (Prymula & Schuerman, 2009).
74
Since 1996, hospital-based surveillance for pneumococcal antibiotic resistance and
75
capsular serotypes associated with pneumococcal meningitis has been conducted in
76
Salvador, Bahia (de O. Menezes et al., 2011; dos Santos et al., 2015; Leite et al., 2016).
77
Here we describe the genetic diversity and antimicrobial susceptibility of S. pneumoniae
78
non-PCV10 serotype isolates recovered from patients with meningitis before (January
79
2008–May 2010) and after (June 2010–December 2012) the introduction of PCV10 in
80
Salvador, Bahia.
81
METHODS
82
Study population and surveillance system. In 1996, an active surveillance system for
83
pneumococcal meningitis cases was initiated at the Hospital Couto Maia, a reference
84
public hospital for infectious diseases with 120 beds, which functions as the medical
85
attendance centre for meningitis in the metropolitan region of the Salvador municipality
4
86
(3,573,973 inhabitants, 2010 IBGE census). The state health department requires all
87
suspected meningitis cases from the region to attend this hospital, and more than 90% of
88
meningitis reports from the region are reported at this unit (DATASUS, 2015). Our
89
technicians reviewed the daily clinical laboratory records at the hospital to identify all S.
90
pneumoniae isolates obtained from symptomatic patients with meningitis with positive
91
cerebrospinal fluid (CSF) and fulfilling the criteria for bacterial meningitis (≥ 100
92
leukocytes/mm3). The pneumococcal isolates identified in this hospital were sent to the
93
Instituto Gonçalo Moniz, Salvador, Brazil for confirmation.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
94 95
Microbiological procedures. Pneumococcal strains were identified by standard
96
methods, including Gram stain, colony morphology on agar media with 5% sheep
97
blood, optochin susceptibility (5-µg Oxoid disks) and bile solubility (Werno &
98
Murdoch, 2008). Capsular serotypes were determined by multiplex-PCR (Dias et al.,
99
2007; CDC, 2014). Quellung reaction tests were performed by the Streptococcus
100
Laboratory at CDC, Atlanta, for all serotypes not resolved by PCR assay, as well as for
101
10% of the serotypes resolved by PCR, as a quality control measure. Antimicrobial
102
susceptibility to penicillin, cefotaxime, clindamycin, chloramphenicol, erythromycin,
103
levofloxacin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin (Sigma-
104
Aldrich, Germany) was assessed by broth microdilution according to Clinical and
105
Laboratory Standards Institute (CLSI) guidelines (CLSI, 2014). The reference strain S.
106
pneumoniae ATCC 49619 was used for quality control. All isolates with minimal
107
inhibitory concentration (MIC) values ≥ 0.12 µg/mL were defined as pneumococcal
108
non-susceptible to penicillin.
109
For comparison purposes, non-PCV10 serotypes were separated into two periods: 1)
110
Pre-vaccine period (January 2008 to June 2010), with 50 (52.1%) isolates, and 2) post-
111
vaccine (July 2010 to December 2012), with 27 (52%) isolates.
112 113
Molecular characterisation. Non-PCV10 isolates were characterised by pulsed-field
114
gel electrophoresis (PFGE). Chromosomal digests generated by SmaI were prepared and
115
analysed as described elsewhere (McEllistrem et al., 2000). Fragments were separated
116
by PFGE in 2% agarose gels using CHEF-DRII apparatus (Bio-Rad Laboratories,
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
5
117
Hercules, CA) with pulse times of 2 to 30 s for 19 h at 14°C and 6 V/cm. Restriction
118
profiles were analysed using the GelCompar II software package (version 4.0; Applied
119
Maths, Bionumerics) to compare the band patterns. PFGE patterns were clustered by the
120
unweighted-pair group method using average linkages (UPGMA), and a dendrogram
121
was generated from a similarity matrix calculated using the Dice similarity coefficient,
122
with an optimization of 1.0% and a tolerance of 1.5%. PFGE patterns were defined as
123
isolates with a similarity of ≥ 80% in the dendrogram. According to PFGE clustering
124
analysis, based on similarity profiles, a random sample of all of isolates showing high
125
relatedness (≥ 80%) from the pre- (26/50 isolates) and post- (14/27 isolates) PCV10
126
periods were selected for MLST analysis, according to an adaption of the method
127
described by Enright & Spratt (1998) (detailed at
128
http://www.cdc.gov/ncidod/biotech/strep/alt-MLST-primers.htm).
129 130
Data analysis. Epidemiological and laboratory information were entered into a standard
131
database and analysed using Epi-Info Version 3.5.1 (CDC, Atlanta, GA). We calculated
132
annual incidence rates (cases per 100,000 population) by dividing the number of cases
133
among residents of the Salvador municipality by the estimated population, using 2010
134
census bureau data to calculate rates for 2008 through 2012 (IBGE, 2010). Fisher’s
135
exact or chi-square tests were used to compare differences between proportions for
136
dichotomous variables. All p values were based on two-sided tests, and p < 0.05 was
137
considered statistically significant.
138 139
Ethical approval: Informed consent procedures were applied to all patients and/or
140
guardians of patients included in this study, which was approved by the National
141
Committee for Research Ethics (CONEP) and the FIOCRUZ Institutional Review
142
Board, Brazilian Ministry of Health (no. 044/2013). All patients or legal guardians gave
143
written informed consent prior to enrolment of subjects in the study.
144 145
RESULTS
146
Overall patient characteristics
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
6
147
A total of 148 cases of pneumococcal meningitis were identified from January 2008 to
148
December 2012, 77/148 (52%) of which were due to non-PCV10 isolates, with 50/96
149
(52.1%) from pre-vaccine and 27/52 (52%) from post-vaccine periods (Table 1). Total
150
non-PCV10 cases consisted of 32.5% women and 67.5% men (Table 1). Of the 71
151
patients for whom age information was available, 8 (16.5%) were children aged ≤ 5
152
years that occurred only in the pre-PCV10 period (p = 0.04). The majority of cases were
153
diagnosed among adults aged between 19–49 years (41.7% and 60.9% from the pre- and
154
post-vaccine periods, respectively) and ≥ 50 years (22.9% and 26.1%, from the pre- and
155
post-vaccine periods, respectively). Differences in the number of days of hospitalization
156
(14 vs. 22; p = 0.04) and in the CSF protein content (300 md/dL vs. 500 md/dL; p =
157
0.03) were observed between the pre- and the post-vaccine periods. No differences were
158
observed in respect of antibiotic resistance or acute illness preceding meningitis.
159
The annual incidence of pneumococcal meningitis (PCV10 and non-PCV10 cases)
160
decreased from 0.9/100,000 inhabitants (30 cases) in 2008 to 0.36/100,000 (12 cases)
161
inhabitants in 2012 (p < 0.05). Fig. 1 shows the annual incidence of pneumococcal
162
meningitis stratified by PCV10 and non-PCV10 cases during the study period. In
163
general, there was a decrease in the incidence of both PCV10 and non-PCV10 cases
164
during the study period. In particular, we observed a decrease in the incidence of non-
165
PCV10 cases from 0.69/100,000 inhabitants in 2008 to 0.21/100,000 inhabitants in 2012
166
(p < 0.76). For PCV10 cases, the incidence reduced from 0.57/100,000 inhabitants in
167
2010 to 0.21/100,000 inhabitants in 2012 (p < 1.0) after the introduction of the PCV10
168
vaccine in June 2010.
169 170
Serotype distribution and antimicrobial susceptibility
171
Over the study period, 28 different serotypes were found: six occurred only in the post-
172
vaccine period (10F, 11A, 21, 22F, 23B, and 24F), whereas ten serotypes (6A, 6C, 17F,
173
18A, 19A, 20, 23A, 28A, 35F, and 38) were identified only in the pre-vaccine period.
174
Twelve serotypes were found in both periods (3, 7C, 8, 9N, 10A, 12F, 13, 15B, 16F,
175
18B, 34, and 35B). In the pre-vaccine period, the most frequent non-PCV10 serotypes
176
were as follows: 3 (n = 6, 12%), 19A (n = 4, 8%), and 6A (n = 4, 8%). In the post-
177
vaccine period, non-PCV10 serotypes 12F (n = 6, 22.2%), 10A (n = 3, 11.1%), 15B (n =
7
178
2, 7.4%), and 18B (n = 2, 7.4%) were the most prevalent. A slight increase in the
179
number of 12F serotype cases was detected in the post-vaccine period (Fig. 2).
180
Of 77 non-PCV10 isolates characterised, 43 (55.8%) were non-susceptible to one or
181
more antibiotics. All isolates were susceptible to cefotaxime, clindamycin,
182
chloramphenicol, levofloxacin, and vancomycin. A total of 28 (36.4%) and 16 (20.8%)
183
isolates were resistant to trimethoprim-sulfamethoxazole and tetracycline, respectively.
184
Serotypes 19A (3 isolates), 9N (1 isolate), and 12F (1 isolate) were not susceptible to
185
penicillin. One isolate (serotype 21) from the post-vaccine period was erythromycin-
186
resistant (Fig. 3).
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
187 188
PFGE and MLST analysis
189
We identified 45 isolates grouped into 19 PFGE profiles with ≥ 80% similarity. Among
190
those profiles, 14/19 (73.7%) and 5/19 (26.3%) occurred in the pre- and post-vaccine
191
periods, respectively. Overall, 32/77 (41.5%) of isolates were not clustered due to
192
exhibiting < 80% similarity in PFGE, with higher variability in the post-vaccine period
193
(17/27; 63%). Sequence types (STs) 80 (n = 3 isolates), 193 (n = 2 isolates), and 8376
194
(n = 2 isolates; serotype 12F) were found in both pre- and post-vaccine periods. The two
195
12F isolates (ST8376) were susceptible and resistant to penicillin in the pre-vaccine and
196
post-vaccine periods, respectively. Seven STs were newly assigned in our study, of
197
which five were from the pre-vaccine period (ST9678, ST9679, ST9680, ST9070, and
198
ST9071), one from the post-vaccine period (ST9681), and was one detected in both
199
periods (ST8376). Furthermore, in the pre-vaccine period, two serotypes (3 and 35B)
200
were found to belong to the same ST (ST180), while in the post-vaccine period,
201
serotypes 12F and 21 (resistant to STX and ERI) showed identical PFGE profile and the
202
same ST (ST218).
203 204
DISCUSSION
205
In Brazil, the introduction of PCV10 to the childhood immunisation schedule in 2010
206
resulted in several changes in the epidemiology of cases of pneumococcal meningitis; in
207
particular, we observed an overall decrease in the number of cases. During the years
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
8
208
following its introduction, vaccination coverage rates improved dramatically, with
209
38,035 doses applied in 2011 (73% of the target population) and 42,415 doses applied
210
in 2012 (81.5% of the target population)—levels which are considered satisfactory
211
(DATASUS, 2015).
212
We did not observe any post-PCV10 emergence of a particular serotype in this study.
213
The PCV10 vaccine was only recently introduced to our region, and 2010 was a year of
214
transition. Furthermore, comparison of the number of 12F, 10A, 15B, and 18B serotype
215
isolates identified in the post-vaccine period with those obtained in past years indicated
216
a normal fluctuation of these serotypes over the years, with no evidence of specific
217
emergence of any particular serotype (data not shown). Fluctuations in the prevalence of
218
a particular serotype may occur naturally in the population of pneumococci, even in the
219
absence of the selective pressure imposed by the use of conjugate vaccines (Finland &
220
Barnes, 1977; Lagos et al., 2008; Ruckinger et al., 2008). Continued surveillance over a
221
longer period is needed to fully assess the impact of vaccine introduction in our region
222
on the pneumococci population.
223
In this study, only four isolates of serotype 19A were identified in the pre-vaccine
224
period. These findings are in agreement with those of dos Santos et al. (2013) in São
225
Paulo, which did not show an increased incidence of this serotype in that city during the
226
post-vaccine period (dos Santos et al., 2013). The incidence of serotype 19A has
227
remained low and stable in Latin America and the Caribbean for 20 years (Castaneda et
228
al., 2012), and a recent study in Brazil demonstrated the specific effectiveness of
229
PCV10 against serotype 19A (Domingues et al., 2014). Regarding antimicrobial
230
susceptibility, three of four serotype 19A isolates identified in the pre-vaccine period
231
were penicillin-non-susceptible. In the United States, after PCV7 vaccination, serotype
232
19A emerged as an important cause of invasive pneumococcal disease, and the most
233
common 19A clones were associated with increased multi-resistance to penicillin and
234
other antimicrobials (Pilishvili et al., 2010).
235
Studies of the immunogenicity of the PCV10 vaccine show that, although it is active
236
against serotype 6A, its activity is approximately 33%–50% lower than that observed
237
with PCV7. Therefore, it is not yet clear whether PCV10 induces cross-protection
238
against serotype 6A (Vesikari et al., 2011; Farkouh et al., 2012). In this study, serotype
239
6A was found only in the pre-vaccine period.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
9
240
Of the 77 isolates characterised in this study, 43 (55.8%) exhibited resistance to at least
241
one antimicrobial, and 13.5% of the isolates (n = 7) showed resistance to two or more
242
antibiotics. Multidrug resistance to antibiotics in S. pneumoniae is undoubtedly a cause
243
for concern. However, in the United States, the introduction of PCV13 in 2010 led to a
244
reduction in resistant infections (Moore et al., 2015).
245
The evidence of non-susceptibility to penicillin in the single serotype 12F isolate of the
246
post-vaccination period suggests that this serotype should be followed in the
247
epidemiological surveillance system in our region, especially if this lineage becomes
248
established as the most prevalent over time. A prospective study with a longer period of
249
monitoring may provide conclusive information. The resistance to trimethoprim-
250
sulfamethoxazole (39%) and tetracycline (20.8%) observed in this study is consistent
251
with previous work in our region (de O. Menezes et al., 2011), and with another
252
national study (Brandileone et al., 2006) and, may be partly associated with the previous
253
use of antimicrobials. We found resistance to erythromycin in only one isolate (serotype
254
21) of the post-vaccine period, in contrast to observations elsewhere; in fact, in the
255
U.S.A. macrolide resistance is overtaking penicillin-resistance, due to the removal of
256
PCV13 strains (especially 19A), leaving serotypes like 33F which are primarily
257
macrolide-resistant (Metcalf et al., 2015).
258
Genotypic characterisation of the S. pneumoniae isolates by PFGE showed great genetic
259
diversity among the non-PCV10 serotypes in the post-vaccine period (63%). In the pre-
260
vaccine period, one 9N isolate was identified as belonging to ST66. It is important to
261
note that this ST, associated with serotype 14, is considered one of the leading and most
262
prevalent clones associated with invasive disease in Salvador and other regions of
263
Brazil (Brandileone et al., 1997; Reis et al., 2008). ST180 (serotype 3), ST193 (serotype
264
18B), and ST218 (serotype 12F) identified in our study are related to the globally
265
disseminated clones, Netherlands3-31, Greece21-30, and Denmark12F-34, respectively, as
266
described by the Pneumococcal Molecular Epidemiology Network (PMEN)
267
(http://web1.sph.emory.edu/PMEN/). This molecular surveillance also encountered
268
similar PFGE profiles (relatedness ≥ 80%) exhibiting different capsular serotypes,
269
suggesting the occurrence of capsular switching events in this epidemiological setting.
270
However, this finding requires careful interpretation and further investigation using a
271
more complete molecular approach.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
10
272
As pointed out by Afonso et al. (2013), any study that uses a temporal method to
273
determine the initial effects of a vaccine can be subject to variation depending on
274
vaccination coverage and the natural lag period between the start of a vaccination
275
program and protection in a population (Afonso et al., 2013). This study was conducted
276
in the pre- and early post-implementation stages of the PCV10 vaccine program in a
277
large urban centre and any conclusions that can be drawn from the results obtained here
278
should be considered preliminary observations of the distribution and molecular
279
characteristics of non-PCV10 serotypes in our region in the post-vaccine period. The
280
scenario that we describe here could change as the use of the PCV10 vaccine is
281
expanded and a larger number of isolates can be studied. The limitations of this study
282
include the small number of isolates and the fact that the data may have been collected
283
too early in the vaccination program to detect replacement strains. Furthermore, the
284
majority of cases were diagnosed in adults (63.4%), a group to which the vaccine does
285
not apply. The effects of the eventual replacement of PCV10 would need an even longer
286
period to be detected.
287 288
It is important to note the evidence of an isolate from the pre-vaccine period expressing
289
capsular type 35B and sequence type 180, which had not been described before in the
290
MLST database (http://spneumoniae.mlst.net/). Similarly, the ST 218 has never
291
previously been identified in serotype 21 (resistant to STX and ERI), which had the
292
same PFGE profile as serotype 12F in our study.
293 294
In conclusion, our study demonstrates that, during the early period following PCV10
295
introduction, no obvious emergence of a particular serotype was evident among non-
296
PCV10 strains. Further studies are necessary to confirm the occurrence of capsular
297
switch events in those serotypes presenting the same PFGE profile and the same ST.
298
The results of our study provide the basis for future analyses regarding the effects of
299
vaccination in the years following PCV10 introduction and for monitoring changes in
300
population biology associated with vaccine introduction.
301 302
ACKNOWLEDGEMENTS
303
We thank Ana Paula de Oliveira Menezes for her help with PCR assays. We are also
304
grateful to Silvana Paz for her help in providing sequencing data and to Bernard Beall
11
305
(Centers for Disease Control and Prevention) for full revision of the manuscript. This
306
work was supported by the Conselho Nacional de Desenvolvimento Científico e
307
Tecnológico (483674/2010-9) and Fundação Oswaldo Cruz (PAPES 407551/2012-3).
308 309
ABBREVIATIONS
310
CLSI, Clinical and Laboratory Standards Institute; MLST, multi-locus sequence
311
typing; Non-PCV10, non-vaccine type; PCV10, 10-valent pneumococcal conjugate
312
vaccine; PFGE, pulsed field gel electrophoresis; ST, sequence type.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
313 314
REFERENCES
315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343
Afonso, E. T., Minamisava, R., Bierrenbach, A. L., Escalante, J. J., Alencar, A. P., Domingues, C. M., Morais-Neto, O. L., Toscano, C. M. & Andrade, A. L. (2013). Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 19, 589-597. Brandileone, M. C., Casagrande, S. T., Guerra, M. L., Zanella, R. C., Andrade, A. L. & Di Fabio, J. L. (2006). Increase in numbers of beta-lactam-resistant invasive Streptococcus pneumoniae in Brazil and the impact of conjugate vaccine coverage. J Med Microbiol 55, 567-574. Brandileone, M. C., Vieira, V. S., Casagrande, S. T., Zanella, R. C., Guerra, M. L., Bokermann, S., De Moraes, J. C., Baldacci, E. R., Chamone, C. B. & other authors (1997). Prevalence of serotypes and antimicrobial resistance of Streptococcus pneumoniae strains isolated from Brazilian children with invasive infections. Pneumococcal Study Group in Brazil for the SIREVA Project. Regional System for Vaccines in Latin America. Microb Drug Resist 3(2), 141146. Calix, J. J., Dagan, R., Pelton, S. I., Porat, N. & Nahm, M. H. (2012). Differential occurrence of Streptococcus pneumoniae serotype 11E between asymptomatic carriage and invasive pneumococcal disease isolates reflects a unique model of pathogen microevolution. Clin Infect Dis 54, 794-799. Castaneda, E., Agudelo, C. I., De Antonio, R., Rosselli, D., Calderon, C., OrtegaBarria, E. & Colindres, R. E. (2012). Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010. BMC Infect Dis 12, 124. CDC. Centers for Disease Control and Prevention (2014). PCR deduction of pneumococcal serotypes. Retrieved 06/06/15, 2015, from http://www.cdc.gov/streplab/pcr.html. CLSI. Clinical and Laboratory Standards Institute (2014). Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement. C. D. M100-S24. Wayne, PA.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
12
344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391
DATASUS. Departamento de Informática do Sistema Único de Saúde (2015). Tecnologia da Informação a Serviço do SUS - Informações da Saúde. Retrieved 06/06/15, 2015, from http://tabnet.datasus.gov.br/cgi/deftohtm.exe?pni/CNV/CPNIBA.def. de O. Menezes, A. P., Campos, L. C., dos Santos, M. S., Azevedo, J., Dos Santos, R. C., Carvalho Mda, G., Beall, B. W., Martin, S. W., Salgado, K. & other authors (2011). Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae prior to introduction of the 10-valent pneumococcal conjugate vaccine in Brazil, 2000-2007. Vaccine 29, 1139-1144. Domingues, C. M., Verani, J. R., Montenegro Renoiner, E. I., de Cunto Brandileone, M. C., Flannery, B., de Oliveira, L. H., Santos, J. B. & de Moraes, J. C. (2014). Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2, 464-71. dos Santos, M. S., Azevedo, J., Menezes, A. P., Cordeiro, S. M., Escobar, E. C., Lima, J. B., Campos, L. C., Carvalho Mda, G., Reis, M. G. & other authors (2015). Temporal trends and clonal diversity of penicillin non-susceptible pneumococci from meningitis cases from 1996 to 2012, in Salvador, Brazil. BMC Infect Dis 15, 302-312. dos Santos, S. R., Passadore, L. F., Takagi, E. H., Fujii, C. M., Yoshioka, C. R., Gilio, A. E. & Martinez, M. B. (2013). Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation. Vaccine 31, 6150-6154. Enright, M. C. & Spratt, B. G. (1998). A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144, 3049-3060. Farkouh, R. A., Klok, R. M., Postma, M. J., Roberts, C. S. & Strutton, D. R. (2012). Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines 11, 12351247. Feldman, C. & Anderson, R. (2014). Review: current and new generation pneumococcal vaccines. J Infect 69, 309-325. Finland, M. & Barnes, M. W. (1977). Changes in occurrence of capsular serotypes of Streptococcus pneumoniae at Boston City Hospital during selected years between 1935 and 1974. J Clin Microbiol 5, 154-166. Geno, K. A., Gilbert, G. L., Song J. Y., Skovsted I.C., Klugman, K. P., Jones, C., Konradsen, H. B. & Nahm, M. H. (2015). Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev 28, 871-99. Hammitt, L. L., Akech, D. O., Morpeth, S. C., Karani, A., Kihuha, N., Nyongesa, S., Bwanaali, T., Mumbo, E., Kamau & other authors. (2014). Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2, e397-405. IBGE. Instituto Brasileiro de Geografia e Estatística (2010). Resultado do censo populacional de Salvador e cidades na área metropolitana, Bahia. Retrieved 10/06/2015, 2015.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
13
392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439
Lagos, R., Munoz, A., San Martin, O., Maldonado, A., Hormazabal, J. C., Blackwelder, W. C. & Levine, M. M. (2008). Age- and serotype-specific pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994-2007. J Infect Dis 198, 1809-1817. Leite, C. R., Azevedo, J., Galvão, V. S., Moreno-Carvalho, O., Reis, J. N. & Nascimento-Carvalho, C. (2015). Clinical and bacteriological characteristics of invasive pneumococcal disease after pneumococcal 10-valent conjugate vaccine implementation in Salvador, Brazil. Braz J Infect Dis 20, 56-60. McEllistrem, M. C., Stout, J. E. & Harrison, L. H. (2000). Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae. J Clin Microbiol 38, 351-353. Metcalf, B. J., Gertz, Jr., R. E., Gladstone, R. A., Walker, H., Sherwood, L. K., Jackson, D., Li, Z., Law, C., Hawkins, P. A. & other authors (2015). Strains features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect 22, 60.e9-60.e29 Millar, E. V., Watt, J. P., Bromsdon, M. A., Dallas, J., Reid, R., Santosham, M. & O ´Brien, K. L. (2008). Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 47, 989-996. Moore, M. R., Link-Gelles, R., Schaffner, W., Lynfield, R., Lexau, C., Bennett, N. M., Petit, S., Zansky, S. M., Harrison, L. H. & other authors (2015). Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis 15, 301-309. O'Brien, K. L., Wolfson, L. J., Watt, J. P., Henkle, E., Deloria-Knoll, M., McCall, N., Lee, E., Mulholland, K., Levine, O. S. & Cherian, T. (2009). Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 893-902. Oliver, M. B., van der Linden, M. P., Küntzel, S.A., Saad, J. S., Nahm, M.H. (2013). Discovery of Streptococcus pneumoniae serotype 6 variants with glycosyltransferases synthesizing two differing repeating units. J Biol Chem 288, 25976–85. Pilishvili, T., Lexau, C., Farley, M. M., Hadler, J., Harrison, L. H., Bennett, N. M., Reingold, A., Thomas, A., Schaffner, W. & other authors (2010). Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 201, 32-41. Prymula, R. & Schuerman, L. (2009). 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 8, 1479-1500. Reis, J. N., Palma, T., Ribeiro, G. S., Pinheiro, R. M., Ribeiro, C. T., Cordeiro, S. M., da Silva Filho, H. P., Moschioni, M., Thompson, T. A. & other authors (2008). Transmission of Streptococcus pneumoniae in an urban slum community. J Infect 57, 204-213. Ruckinger, S., von Kries, R., Reinert, R. R., van der Linden, M. & Siedler, A. (2008). Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Vaccine 26, 3984-3986.
14
440 441 442 443 444 445 446 447 448 449 450 451 452
Dias, C. A., Teixeira, L. M., Carvalho, M. da G., Beall, B. (2007). Sequential multiplex PCR for determining capsular serotypes of pneumococci recovered from Brazilian children. J Med Microbiol 56, 1185-8. Vesikari, T., Karvonen, A., Korhonen, T., Karppa, T., Sadeharju, K., Fanic, A., Dieussaert, I. & Schuerman, L. (2011). Immunogenicity of 10-valent pneumococcal nontypeable Haemophilus Influenzae Protein D Conjugate Vaccine when administered as catch-up vaccination to children 7 months to 5 years of age. Pediatr Infect Dis J 30, e130-141. Werno, A. M. & Murdoch, D. R. (2008). Medical microbiology: laboratory diagnosis of invasive pneumococcal disease. Clin Infect Dis 46, 926-932. World Health Organization – WHO (2012). Pneumococcal vaccines - WHO position paper. Retrieved 02/07/2016 from http://www.who.int/wer/2012/wer8714/en
453
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
454
Figure Titles
455 456 457
Fig. 1. Incidence and number of cases of pneumococcal meningitis in the metropolitan region of Salvador, Brazil, stratified by PCV10 and non-PCV10 serotypes, 2008–2012.
458 459
Fig. 2. Distribution of non-vaccine serotypes among isolates from pneumococcal
460
meningitis cases in the metropolitan area of Salvador, 2010–2012, stratified by pre-
461
vaccine and post-vaccine periods (n = 77).
462 463
Fig. 3. Dendrogram of PFGE molecular profiles of non-PVC10 serotypes isolated from
464
pneumococcal meningitis in the metropolitan area of Salvador. A: Pre-vaccine period (n
465
= 50); B: Post-vaccine period (n = 27).
15
466
Table 1. Characteristics of patients with pneumococcal meningitis caused by non-PCV10 pneumococci before and after vaccination.
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
Characteristics Demographic data Male gender Age groups (years), median (range) ≤5 6–18 19–49 ≥ 50 Clinical information Neurological status at admission* Days of symptoms, median (range) Days of hospitalisation, median (range) ICU admission (days), median (range) Mortality CSF information White cell count (cells/mm3), median (range) Protein (mg/dL), median (range) Glucose (mg/dL), median (range) Cases non-susceptible to: Penicillin Tetracycline Trimethoprim-sulfamethoxazole Erythromycin Acute illness preceding meningitis (%) Pneumonia Acute otitis media Head trauma Upper respiratory tract infection
Pre-PCV10 period n = 50 (100%)
Post-PCV10 period n = 27 (100%)
467
p-value
34 (68%) 26 (10.5–46.5) 8 (16.5%) 9 (18.8%) 20 (41.7%) 11 (22.9%)
18 (69%) 36 (27–53) 0 (0) 3 (13%) 14 (60.9%) 6 (26.1%)
1.00 0.07 0.04 0.58 0.14 0.79
33 (66%) 3 (1–4.5) 14 (11–20) 13 (6–24) 18%
18 (69%) 2 (1–3) 22 (15–32) 10 (7–21) 15%
0.96 0.29 0.03 0.78 0.97
4150 (627–10000) 300 (300 – 500) 20 (20–40)
3840 (1100–10000)
0.91
500 (350–565) 20 (20–32)
0.03 0.60
4 (8%) 13 (26%) 19 (38%) 0 (0)
1 (3.7%) 3 (11.1%) 11 (47.7%) 1 (3.7%)
0.53 0.13 0.82 0.35
6 (12%) 4 (8%) 6 (12%) 12 (24%)
0 (0) 2 (7.7%) 1 (3.9%) 3 (11.5%)
0.65 0.65 1.00 0.19
468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
16
500 *coma or altered mental status; ICU: Intensive care unit (21 patients were admitted).
Figure 1
Click here to download Figure Fig 1.docx
0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 0
35 30 25 20 15 10 5 0
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
2008
2009 2010 2011 Study Year
PCV10 serotypes*
2012
Non-PCV10 serotypes
Numer of cases, overall
Incidence (cases/100,000 inhabitants)
Fig. 1
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
Number of cases
Figure 2 Click here to download Figure Fig 2.docx
Fig. 2
Pre-PCV10 Period
Serotypes
Post-PCV10 Period
Figure 3
Click here to download Figure Fig. 3.docx
Fig. 3 (a)
(b)
Sample Serotype MLST
Resistance
Downloaded from www.microbiologyresearch.org by IP: 158.111.236.10 On: Mon, 12 Sep 2016 20:18:37
profile
ST, sequence type; PEN, penicillin; TET, tetracycline; ERI, erythromycin; SXT, trimethoprim-sulfamethoxazole.
Sample Serotype MLST
Resistance profile